reason report
eas comp make doabl guidanc busi feel
bottom line share trade meaning today reaction
less-bad-than-fear quarter like bit short
squeez impella revenu came y/i
us consensu ahead think buy-
side expect noteworthi stock revenu
headwind quarter open fewer site
quarter vs quarter last year exclud impact stock
sale impella sale deliv y/i growth
growth deceler point comp-adjust basi
us suggest perhap point stabil underli
busi reiter guidanc manag guid
lower end guidanc rang impli
y/i growth back half year despit easier comp comp-
adjust basi impli growth deceler
point vs us suggest guidanc
achiev downsid unlik base
believ on-going growth major centers/us offset
declin volum stock perspect
today ralli put valuat sale
smid-cap med-tech group trade sale overal
think deserv trade premium long-term given
double-digit sale growth profil gross oper margin
profil strong balanc sheet given stock alreadi
low earli octob inclin
think share like rel rang bound year-
end next possibl catalyst follow analyst
meet potenti april/may time-frame
reiter op pt price target vs prior appli
ev/sal multipl estim assum
current multipl hold steadi continu believ
top-tier sale growth profil profit warrant in-lin
consist
wmgiaverag
sale estim move lower toward low-end
ep decreas vs prior reflect
top-line growth vs guidanc rang continu
expect deliv oper margin high-end guidanc
rang ep estim move lower reflect after-tax
non-cash charg per share due mtm
adjust shock wave invest revenue/ep
move
medic suppli devic
ev/sal multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu dilut gaap ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target us
much execut stori compani continu drive adopt impella famili
percutan ventricular assist devic pvad enter next phase
adopt curv admittedli like multi-quart turnaround requir heavi
lift compani still believ double-digit growth sustain even
period transit compani like retain monopoli us heart recoveri
market opportun forese futur time-frame project
sale compound-annual-growth-rate drive adopt current high-risk pci cardiogen shock
indic
highli under-penetrated market opportun penetr
base abmd market assess address patient includ
cardiogen shock patient high-risk pci patient right heart failur
patientsal believ remain intact
geograph expans germani japan manag estim
penetr address patient germani still earli commerci
roll-out address patient market opportun japan
clear strateg plan break barrier adopt motto train data
time compani continu train physician build clinic data still
balloon pump use cardiogen shock patient today compar
estim impella implant given balloon pump
deem class devic countri like germani japanmean
actual caus harm usedit seem clear us technolog eventu becom
obsolet impella viabl replac believ barrier adopt
gradual broken awar spread still-build clinic dataset
train continu ramp
believ drive solid double-digit sale growth exist cardiogen
shock high-risk pci indic view potenti indic expans stemi
st-elev myocardi infarct could ultim doubl exist total
address market todaya call option compani recent receiv
fda approv initi stemi triala prospect multi-cent two-arm trial plan
enrol patient undergo treatment stemi heart attack enrol begin
octob expect finish date time frame
beyond double-digit sale growth monopoli pvad space also offer one
compel margin profil coverag univers gross margin
oper margin leverag ultim push oper margin
believ repres uniqu asset smid-cap med-tech
price target appli ev/sal multipl sale
estim assum current sale multipl hold steadi believ upsid
share near term limit beat rais difficult come
light potenti slower ramp adopt next wave adopt requir focu
effort part compani drive adopt
risk rate valuat includ failur drive increas util rate
and/or continu add new account steadi rate failur execut pipelin
launch new geographi potenti reimburs declin potenti competit
pvad product secur approv gain meaning market share potenti
dollar million except per share data
total good sold
research develop expens
consensu incom statement item includ contributor factset
revenu
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
servic revenu
consensu detail revenu item visibl alpha
consensu
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
total good sold
research develop
cog sale
sg sale
 sale
oper expens sale
compani report svb leerink estim
share-bas
pivot compar today standard care immedi reperfus without
ecp expand cardiac power true cathet target three
liter flow ideal pump high-risk pci physician want
anyth larger way pump short
area inflow valv thin soft membran abras
valv ecp deliv design clinic durat
hour fr pump expand fr
impella btr expect later outer year estim flow l/min
cathet fr pump shorter design durat month year
also wearabl driver allow patient get discharg
hospit impella btr minim invas approach axillari arteri
bridg
 jan close final
detail trial fda expect
start second half
 manag expect first patient octob
 octob manag expect
first patient next three week
plan begin enrol octob
still pre-clin test aug
-a februari first-in-man ecp still
expect
 jan first-in-man ecp expect
 octob manag expect
first patient end march
